1. Search Result
Search Result
Results for "

Y

" in MedChemExpress (MCE) Product Catalog:

742

Inhibitors & Agonists

10

Fluorescent Dye

9

Biochemical Assay Reagents

252

Peptides

6

Inhibitory Antibodies

53

Natural
Products

45

Recombinant Proteins

52

Isotope-Labeled Compounds

18

Antibodies

7

Click Chemistry

14

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10067
    Y-33075
    10+ Cited Publications

    Y-39983 free base

    ROCK Cancer
    Y-33075 is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM.
    Y-33075
  • HY-101069
    Y-26763
    1 Publications Verification

    Potassium Channel Cardiovascular Disease
    Y-26763 is a K + channel opener and active metabolite of Y-27152 . Y-26763 is an ATP-sensitive K + (KATP) channel activator .
    Y-26763
  • HY-10583R
    Y-27632 dihydrochloride (Standard)
    Maximum Cited Publications
    259 Publications Verification

    ROCK Organoid Cancer
    Y-27632 (dihydrochloride) (Standard) is the analytical standard of Y-27632 (dihydrochloride). Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects .
    Y-27632 dihydrochloride (Standard)
  • HY-15898
    Y-320
    3 Publications Verification

    Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer .
    Y-320
  • HY-145837

    Neuropeptide Y Receptor Cancer
    Y1R probe-1 (Compound 39) is a high-affinity fluorescence probe for the Neuropeptide Y Y1 Receptor. Y1R probe-1 has the potential for the research of cancer disease .
    Y1R probe-1
  • HY-10068

    Y-39983

    ROCK Neurological Disease
    Y-33075 hydrochloride (Y-39983) is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM.
    Y-33075 hydrochloride
  • HY-19082

    GABA Receptor Neurological Disease
    Y-23684 is a partial agonist of benzodiazepine receptor (BZR) with anticonvulsant and anxiolytic activities. Y-23684 can be used in the research of treatment of anxiety disorders .
    Y-23684
  • HY-15113A

    Prolyl Endopeptidase (PREP) Neurological Disease Cancer
    Y-29794 tosylate is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC50 of 3 nM and a Ki of 0.95 nM. Y-29794 tosylate enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 tosylate exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 tosylate penetrates the brain-blood barrier (BBB) .
    Y-29794 tosylate
  • HY-15113

    Prolyl Endopeptidase (PREP) Neurological Disease Cancer
    Y-29794 is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC50 of 3 nM and a Ki of 0.95 nM. Y-29794 enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 penetrates the brain-blood barrier (BBB) .
    Y-29794
  • HY-100258

    Others Cardiovascular Disease
    Y-9738 is a hypolipidemic agent.
    Y-9738
  • HY-10071A

    Organoid ROCK Apoptosis Cancer
    Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .
    Y-27632 hydrochloride hydrate
  • HY-10071
    Y-27632
    Maximum Cited Publications
    259 Publications Verification

    Organoid ROCK Apoptosis Cancer
    Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .
    Y-27632
  • HY-108582

    Potassium Channel Cardiovascular Disease
    Y-27152, a proagent of the KATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state .
    Y-27152
  • HY-10583G

    ROCK Neurological Disease Cancer
    Y-27632 dihydrochloride (GMP) is the GMP level of Y-27632 dihydrochloride (HY-10583). GMP guidelines are used to produce Y-27632 dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor with antiepileptic effect .
    Y-27632 dihydrochloride
  • HY-10069
    Y-33075 dihydrochloride
    10+ Cited Publications

    ROCK Cancer
    Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM.
    Y-33075 dihydrochloride
  • HY-10583
    Y-27632 dihydrochloride
    Maximum Cited Publications
    259 Publications Verification

    Organoid ROCK Neurological Disease Cancer
    Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects .
    Y-27632 dihydrochloride
  • HY-123013

    Others Inflammation/Immunology
    Y 9000 is an orally active anti-allergic agent .
    Y 9000
  • HY-157134

    Others Cancer
    Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC50 value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML) .
    Y08262
  • HY-103471

    FAK Cancer
    Y11 inhibits FAK1 autophosphorylation by blocking phosphorylation of Y397 and decreases tumor growth .
    Y11
  • HY-107758

    Prolyl Endopeptidase (PREP) Cancer
    Y-29794 oxalate is a selective, orally active and blood-brain barrier permeable non-peptide prolyl endopeptidase inhibitor. Y-29794 oxalate blocks the IRS1-AKT-mTORC1 pathway and inhibits tumor growth. Y-29794 oxalate is also effective in inhibiting the progression of Aβ-like deposition in the hippocampus of aging-accelerated mice (SAM) .
    Y-29794 oxalate
  • HY-142743

    Epigenetic Reader Domain Cancer
    Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC50s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer .
    Y08175
  • HY-114902

    Epigenetic Reader Domain Cancer
    Y02224 is a potent BRD4 inhibitor and exhibits reasonable antiproliferative effect on leukemia cells.Y02224 has the potential for? CRPC research .
    Y02224
  • HY-155131

    Fungal Infection
    Y18501 is a oxysterol-binding protein (OSBPI) inhibitor with a similar structure to Oxathiapiprolin. Y18501 shows strong inhibitory activities against Phytophthora spp. and Pseudoperonospora cubensis, with EC50 ranging from 0.0005 to 0.0046 μg/mL. Y18501 shows excellent protective and curative activities against P. cubensis. Y18501 in combination with Chlorothalonil (HY-N6625) can significantly promote the inhibition of P. cubensis .
    Y18501
  • HY-111503

    Epigenetic Reader Domain Cancer
    Y06137 is a potent and selective BET inhibitor for treatment of castration-resistant prostate cancer (CRPC). Y06137 binds to the BRD4(1) bromodomain with a Kd of 81 nM .
    Y06137
  • HY-17487

    Y 0213; Y 9213

    Others Neurological Disease Inflammation/Immunology
    Miroprofen (Y 0213) is an orally active nonsteroidal anti-inflammatory analgesic (NSAID). Miroprofen exhibits anti-inflammatory, analgesic and anti-platelet activities .
    Miroprofen
  • HY-12649
    Y16
    5 Publications Verification

    Ras Cancer
    Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP .
    Y16
  • HY-103457

    Estrogen Receptor/ERR Cancer
    Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM). Y134 inhibits oestrogen-stimulated proliferation of ER-positive human breast cancer cells .
    Y134
  • HY-B0068
    Azasetron hydrochloride
    2 Publications Verification

    Y-25130 hydrochloride

    5-HT Receptor Neurological Disease
    Azasetron (Y-25130) hydrochloride, a benzamide derivative, is a potent and selective 5-HT3 receptor antagonist. Azasetron is used in the study for Chemotherapy-induced nausea and vomiting (CINV) .
    Azasetron hydrochloride
  • HY-142772

    Epigenetic Reader Domain Cancer
    Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .
    Y08284
  • HY-14669

    Y-700; Piraxostat

    Xanthine Oxidase Metabolic Disease
    Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved .
    Niraxostat
  • HY-106837

    Y 24180

    Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology
    Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca 2+ influx and intracellular Ca 2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .
    Israpafant
  • HY-W032848
    Tinoridine
    1 Publications Verification

    Y-3642

    COX Inflammation/Immunology
    Tinoridine (Y-3642) is an orally active non-steroidal anti-inflammatory agent with potent antiperoxidative ability and radical scavenger activity. Tinoridine acts function by inhibiting COX enzyme, involves in hepatotoxicity inhibition. .
    Tinoridine
  • HY-139839

    Fungal Infection
    Y12196 is a novel succinate dehydrogenase inhibitor (SDHI) which exhibits strong fungicidal activity against F. graminearum.
    Y12196
  • HY-111502

    Epigenetic Reader Domain Cancer
    Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM . Antitumor activity .
    Y06036
  • HY-115910A

    Interleukin Related Cholinesterase (ChE) Neurological Disease
    Y13g dihydrochloride is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g dihydrochloride reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g dihydrochloride
  • HY-115910

    Cholinesterase (ChE) Interleukin Related Neurological Disease
    Y13g is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g
  • HY-101704

    H 409-22 (isomer)

    Neurokinin Receptor Neurological Disease Endocrinology
    Y1 receptor antagonist 1 (H 409-22 isomer) is a neuropeptide Y1 receptor antagonist.
    Y1 receptor antagonist 1
  • HY-101704A

    H 409-22 isomer formic

    Neurokinin Receptor Neurological Disease
    Y1 receptor antagonist 1 formic (H 409-22 isomer formic) is the formic salt form of Y1 receptor antagonist 1 (HY-101704). Y1 receptor antagonist 1 formic is a neuropeptide Y1 receptor antagonist.
    Y1 receptor antagonist 1 formic
  • HY-12444
    Y15
    15+ Cited Publications

    FAK Inhibitor 14

    FAK Cancer
    Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
    Y15
  • HY-111073

    Y101

    HBV Infection Inflammation/Immunology
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields .
    Bentysrepinine
  • HY-123558

    Y 14556

    Others Cancer
    Bactobolin C is an antibiotic produced by Pseudomonas sp. BMG13A7, which has strong antimicrobial and antitumor activities, can also inhibit antibody production and treat autoimmune encephalomyelitis. However, its undesirable toxicity limits its medicinal application. The unique chemical structure and promising biological activities of Bactobolin C have attracted people's interest in its total synthesis and new active analogs. So far, the structural modification of Bactobolin C has mainly focused on the hydroxyl groups on the amino acid side chains and backbone.
    Bactobolin C
  • HY-111354
    Tinoridine hydrochloride
    1 Publications Verification

    Y-3642 hydrochloride

    Glutathione Peroxidase Inflammation/Immunology
    Tinoridine hydrochloride is a nonsteroidal anti-inflammatory agent and also has potent radical scavenger and antiperoxidative activity.
    Tinoridine hydrochloride
  • HY-110156

    Others Cancer
    Y29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 µM, and acts as a competitive inhibitor against Fru-6-P with a Ki of 0.094 µM. Y29 also inhibits the HeLa cell growth with a GI50 of 2.7 µM .
    YZ9
  • HY-136182A

    Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769
  • HY-136182

    Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 dihydrochloride is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 dihydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 dihydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 dihydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769 dihydrochloride
  • HY-107659

    Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 hydrochloride is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769 hydrochloride
  • HY-111557
    YM-254890
    5+ Cited Publications

    P2Y Receptor Cardiovascular Disease
    YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM .
    YM-254890
  • HY-P3676

    Neuropeptide Y Receptor Neurological Disease
    Neuropeptide Y (3-36) (porcine) is an agonist of neuropeptide Y (NPY) receptor subtype Y2, and stimulates feeding in rats. Neuropeptide Y (3-36) (porcine) is a highly Y2 selective ligand compared with nselective Y1/Y2 receptor ligand, Neuropeptide Y 1-36 .
    Neuropeptide Y (3-36) (porcine)
  • HY-P3678

    Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure .
    Neuropeptide Y (18-36) (porcine)
  • HY-N10535

    Lewis y

    FAK Cancer
    Lewis Y tetrasaccharide (Lewis Y, Le Y) is a tetrasaccharide derivative form of Lewis X trisaccharide (HY-N10534). Lewis Y tetrasaccharide is an antigen associated with malignant ovarian carcinomas metastasis and poor prognosis .
    Lewis y tetrasaccharide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: